LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more
LegoChem Biosciences Inc (141080) - Total Liabilities
Latest total liabilities as of September 2025: ₩136.37 Billion KRW
Based on the latest financial reports, LegoChem Biosciences Inc (141080) has total liabilities worth ₩136.37 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LegoChem Biosciences Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how LegoChem Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LegoChem Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of LegoChem Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huaxin Cement Co Ltd A
SHG:600801
|
China | CN¥41.79 Billion |
|
Addsino Co Ltd
SHE:000547
|
China | CN¥4.74 Billion |
|
VSE Corporation
NASDAQ:VSEC
|
USA | $577.11 Million |
|
Haci Omer Sabanci Holding AS
IS:SAHOL
|
Turkey | TL3.19 Trillion |
|
Kobe Bussan Co. Ltd.
PINK:KOBNF
|
USA | $98.88 Billion |
|
Brady Corporation
NYSE:BRC
|
USA | $512.18 Million |
|
Humanwell Healthcare Group Co Ltd
SHG:600079
|
China | CN¥16.15 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down LegoChem Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LegoChem Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LegoChem Biosciences Inc (2014–2024)
The table below shows the annual total liabilities of LegoChem Biosciences Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩122.38 Billion | +196.47% |
| 2023-12-31 | ₩41.28 Billion | +25.35% |
| 2022-12-31 | ₩32.93 Billion | -4.43% |
| 2021-12-31 | ₩34.46 Billion | +44.87% |
| 2020-12-31 | ₩23.79 Billion | -14.22% |
| 2019-12-31 | ₩27.73 Billion | +38.49% |
| 2018-12-31 | ₩20.02 Billion | -41.17% |
| 2017-12-31 | ₩34.03 Billion | +15.40% |
| 2016-12-31 | ₩29.49 Billion | +16.74% |
| 2015-12-31 | ₩25.26 Billion | +84.24% |
| 2014-12-31 | ₩13.71 Billion | -- |